Skip to Content

Xinlay Approval Status

  • FDA approved: No
  • Brand name: Xinlay
  • Generic name: atrasentan
  • Company: Abbott
  • Treatment for: Prostate Cancer

Xinlay (atrasentan) is a selective endothelin-A receptor antagonist intended for the treatment of hormone-refractory prostate cancer (HRPC).

In October 2005, Abbott received a not-approvable letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for the oral investigational agent Xinlay. The FDA’s Oncologic Drugs Advisory Committee (ODAC) recommended against the approval of Xinlay in September 2005.

Development Status and FDA Approval Process for Xinlay

Sep 13, 2005FDA Advisory Committee Does Not Recommend Approval of Xinlay (atrasentan)
Feb 11, 2005FDA Agrees to File Abbott's New Drug Application for Xinlay (Atrasentan) to Treat Metastatic Hormone-Refractory Prostate Cancer
Dec 14, 2004Abbott Submits New Drug Application to U.S. FDA for Advanced Prostate Cancer Drug, Xinlay (atrasentan)

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.